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Are Changes in Heart Rate Variability in Middle-Aged and Older
People Normative or Caused by Pathological Conditions? Findings
From a Large Population-Based Longitudinal Cohort Study
Vera K. Jandackova, PhD; Shaun Scholes, PhD; Annie Britton, PhD; Andrew Steptoe, DSc
Background-—No study to date has investigated longitudinal trajectories of cardiac autonomic modulation changes with aging;
therefore, we lack evidence showing whether these changes occur naturally or are secondary to disease or medication use. This
study tested whether heart rate variability (HRV) trajectories from middle to older age are largely normative or caused by
pathological changes with aging in a large prospective cohort. We further assessed whether HRV changes were modiﬁed by
socioeconomic status, ethnicity, or habitual physical activity.
Methods and Results-—This study involved 3176 men and 1238 women initially aged 44 to 69 years (1997–1999) from the UK
Whitehall II population-based cohort. We evaluated time- and frequency-domain HRV measures of short-term recordings at 3 time
points over a 10-year period. Random mixed models with time-varying covariates were applied. Cross-sectionally, HRV measures
were lower for men than for women, for participants with cardiometabolic conditions, and for participants reporting use of
medications other than beta blockers. Longitudinally, HRV measures decreased signiﬁcantly with aging in both sexes, with faster
decline in younger age groups. HRV trajectories were not explained by increased prevalence of cardiometabolic problems and/or
medication use. In women, cardiometabolic problems were associated with faster decline in the standard deviation of all intervals
between R waves with normal-to-normal conduction, in low-frequency HRV, and in low-frequency HRV in normalized units.
Socioeconomic status, ethnicity, and habitual physical activity did not have signiﬁcant effects on HRV trajectories.
Conclusions-—Our investigation showed a general pattern and timing of changes in indices of cardiac autonomic modulation from
middle to older age. These changes seem likely to reﬂect the normal aging process rather than being secondary to cardiometabolic
problems and medication use. ( J Am Heart Assoc. 2016;1:e002365 doi: 10.1161/JAHA.115.002365)
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A substantial amount of research has focused onbiomarkers that identify people at higher risk of
developing cardiovascular disease.1 One indicator that seems
to play a pivotal role is dysfunction of the autonomic nervous
system. Speciﬁcally, increased sympathetic and/or
decreased parasympathetic activity has been associated with
increased risk for a number of cardiac outcomes such as
sudden cardiac death, heart failure, ventricular arrhythmias,
or hypertension.2,3 Heart rate variability (HRV) is a valid
noninvasive technique for estimating the characteristics of
the autonomic nervous system and for quantifying modulation
of the sympathetic and parasympathetic inputs.4,5 Decreased
HRV has been linked to increased mortality in cardiac
patients6,7 and increased risk of coronary heart disease and
cardiac mortality in general populations.8,9 Establishing the
associations between HRV and coronary heart disease
remains problematic because a number of cofactors may
wholly or partially account for the increased risk of coronary
heart disease among persons with decreased HRV. These
factors include age, poor health, physical inactivity, and
medication use as well as socioeconomic status (SES) and
ethnicity.
HRV is believed to decline as people age, but a key
scientiﬁc question is whether falls in HRV occur naturally with
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age as a result of the aging process itself or as a result of
pathogenic processes and/or medication use. A number of
studies have documented the normal changes in HRV that
accompany aging10–16 and HRV changes due to chronic
diseases or health-related conditions.17–21 These studies,
however, have signiﬁcant limitations including a reliance on
cross-sectional data or lack of statistical adjustment for
important factors. The evidence of age-related HRV changes is
based primarily on cross-sectional studies of different age
groups,10,12–16 making it difﬁcult to identify within-person
change. Differences between age groups in cross-sectional
studies could be related to selective survival among older
people rather than genuine effects. A small number of
longitudinal studies on age-related HRV changes have been
conducted.11,17–21 Of these, only a few are population
based,18–21 and others have relied on small samples of
elderly participants.12,13 No studies with large sample sizes
have conducted >2 repeated HRV measurements. Medication
use and/or the existence of prevalent cardiometabolic
problems such as diabetes or stroke may be related to HRV
changes over time. Consequently, the rate and temporal
course of HRV changes are not well understood.
Cardiac autonomic modulation has been found to be
signiﬁcantly inﬂuenced by sex.10,12,14,16 On average, women
have been shown to have reduced sympathetic inﬂuence and
enhanced parasympathetic inﬂuence on heart rate (HR)
relative to men.22 Over time, different ways of responding
to health conditions and medication may inﬂuence the shape
of HRV changes between men and women.
Another relevant factor that contributes to accelerated
aging processes and development and prognosis of cardio-
vascular disease outcomes is SES.23 It is well documented
that persons from lower SES groups have higher risk of
cardiovascular disease outcomes and reduced HRV and
parasympathetic activity than persons from higher SES
groups.24,25 It remains unclear how the associations between
SES and HRV change as people age. Similarly, ethnicity is
associated with HRV levels. On average, people of white
ethnic origin have been shown to have lower HRV than African
Americans,26 whereas studies of differences in HRV levels
between people of South Asian and European origin have
shown inconsistent results.27,28 Evidence of ethnic differ-
ences in changes in HRV over time is limited. Finally, physical
activity has been proposed as a further important determinant
of HRV.29 Maintenance of physical activity as part of the aging
process may have a positive effect on the rate of change in
HRV over time.
Using unique data from a large, longitudinal UK population-
based cohort study with 3 measurements of short-term HRV
over a 10-year period, we sought to test whether HRV
changes were largely normative or caused by pathological
changes with aging. We also examined whether changes in
HRV over time varied systematically by SES, ethnicity, and
habitual physical activity.
Methods
Sample
The Whitehall II cohort study is an ongoing longitudinal study
of 10 308 civil servants (6895 men and 3413 women) based
in London, United Kingdom.30 All civil servants aged 35 to
55 years and employed in 20 London-based white collar civil
service departments were invited to participate in this study,
and recruitment took place from 1985 to 1988. Subsequent
data collection alternated between postal questionnaires
alone and postal questionnaires accompanied by clinical
examination. HR and HRV were measured at the ﬁfth (1997–
1999), seventh (2002–2004), and ninth (2007–2009) phases
of data collection. At phase 5, all study members known to be
alive and resident in the United Kingdom were invited to
attend a screening clinic. Although 6554 participants (1909
women) attended the clinic (67% of participants), HR was
recorded for only 3365 participants because of staff avail-
ability. No HRV recordings were collected on 69 days during
screening, accounting for the majority of missing HRV data at
phase 5. Participants who did not undergo HRV recordings at
phase 5 did not differ signiﬁcantly from those who did with
respect to age, sex, and employment grade.24 To focus on the
estimation of within-person change in HR and HRV levels, we
restricted the analytical sample to the subset of participants
with at least 2 HRV measurements. The analytical sample for
this study comprised 4414 participants (3176 men) with at
least 2 HRV measurements. The University College London
Medical School committee on the ethics of human research
approved the Whitehall II study. Informed consent was
obtained at baseline and renewed at each contact. Whitehall
II data, protocols, and other metadata are available to bona
ﬁde researchers for research purposes. Please refer to the
Whitehall II data sharing policy (http://www.ucl.ac.uk/white-
hallII/data-sharing).
Outcomes
Details on the assessment of HR and HRV in Whitehall II can
be found elsewhere.20,24 Brieﬂy, 5-minute supine resting 12-
lead ECGs were obtained after 5 minutes of rest. Different
ECG recorders were used in the different phases. A Kardiosis
device (Kardiosis Cardiologic Diagnostic Systems), a SEER MC
recorder (GE Medical Systems), and a Getemed recorder
(Getemed Teltow) were used at phases 5, 7, and 9,
respectively. The sampling frequencies and outputs of the
different devices were comparable. Five minutes of beat-to-
beat HR data were sampled at 500 Hz frequency to obtain a
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digitized sequence of R waves. Using an automatic algo-
rithm,31 ECG abnormalities including ectopic beats, right
bundle-branch block, respiratory arrhythmia, blocked atrial
extrasystole, and high-amplitude and wide T waves were
identiﬁed, and normal QRS complexes suited for a reliable
HRV analysis were detected. HRV was analyzed both in the
time domain (standard deviation of all intervals between R
waves with normal-to-normal conduction [SDNN]) and in the
frequency domain using a Blackman-Tukey algorithm. Fre-
quency-domain components were computed by integrating
the power spectrum within 2 frequency bands: 0.04 to
0.15 Hz (low-frequency power [ms2]) and 0.15 to 0.4 Hz
(high-frequency power [ms2]). Low-frequency power (low-
frequency HRV [LF-HRV]) reﬂects both parasympathetic and
sympathetic HR modulations; high frequency (high-frequency
HRV [HF-HRV]) is an index of parasympathetic modulation of
HR.4,5 In addition, we used LF-HRV in normalized units (LFnu
[%]), which was computed as LF/(LF+HF). To avoid redun-
dancy, the HF-HRV in normalized units, being equal to 100%
minus LFnu (%), was not analyzed. These ratio-based HRV
measures have been proposed as indices of sympathovagal
balance.4,5
Covariates
Age at phase 5 (1997–1999) was categorized into 4 groups
(44–49, 50–54, 55–59, and 60–69 years). SES, assessed by
the British civil service employment grade, was categorized
into 3 groups in order of decreasing salary and work role:
administrative (high), professional/executive (middle), and
clerical/support (low). Ethnicity was deﬁned according to the
Ofﬁce for National Statistics 1991 census categories, and
participants were initially categorized into 4 ethnic groups:
white European, South Asian, African Caribbean, and other.
Numbers were too small to examine age- and sex-speciﬁc HR
and HRV trajectories for nonwhite minority ethnic groups.
Physical activity was categorized according to whether
participants adhered to the World Health Organization (WHO)
physical activity guidelines of at least 1 hour of vigorous
activity 3 times or 2.5 hours of moderate activity 5 times per
week.32 These guidelines are widely used and have been
quantitatively validated for cardiovascular outcomes.33 Habit-
ual physical activity over the 10-year period was categorized
as hardly ever (once or less through follow-up), sometimes (in
2 phases), or always (in all 3 follow-up phases) meeting the
WHO guidelines. Cardiometabolic problems at each phase
were assessed as the presence of any of the following chronic
disease or health-related conditions: diagnosed coronary
heart disease including heart failure,9,34 stroke,35 hyperten-
sion,18,20 diabetes,19,29 and obesity.20 These factors were
chosen as covariates based on systematic literature review as
likely to profoundly inﬂuence HRV. At each screening,
participants provided details of current medications taken in
the previous 14 days (generic name, brand name, or both).
Prescribed medication included all drugs taken in the previous
14 days that were prescribed by a doctor such as analgesics,
antihyperlipidemic agents, antidiabetic agents, psychotropic
agents, and antibiotics. We distinguished between beta
blockers (British National Formulary codes, chapter 2.4) and
other prescribed medications because previous studies have
shown the former to have a beneﬁcial effect on HRV levels.36
Other cardiovascular and central nervous system–related
medications have been shown to decrease or have no effect
on HRV levels.17,18
Statistical Analysis
Analyses were performed in Stata 13.1 (StataCorp). All tests
of statistical signiﬁcance were based on 2-tailed probability
(P<0.05). SDNN, LF-HRV, and HF-HRV were transformed by
natural logarithm because their distributions were skewed.
Outliers (mean3 SD) were trimmed to 3 SD from the mean
prior to transformation. Age-adjusted arithmetic and geomet-
ric means and 95% CIs were calculated for the subset of 1658
participants with complete HR and HRV measurements at
each phase of data collection. For this subset of participants,
the change in HR between the ﬁrst and third measurements
was deﬁned as HR at phase 9 minus HR at phase 5, scaled to
a time difference of 10 years. For HRV measurements,
change over time was calculated using the log-transformed
values. Back transformation was applied to present the
percentage change over the 10-year period. Spearman rank
correlation coefﬁcient was used to examine the correlations
between the HR and HRV measures at phase 5.
Two sets of linear mixed models were used to estimate
change in HR and HRV over 10-year follow-up. This method of
estimation uses all available data over follow-up, takes into
account the intraindividual correlation between repeated
measurements, and can handle missing data. The intercept
was ﬁtted as a random effect, allowing participants to have
different HRV values at baseline.37
The ﬁrst set of models was used to examine age-speciﬁc
HRV trajectories without adjusting for any covariates. The
dependent variable was the 3 repeated measurements of HR
and HRV, and the independent variables were time (exact time
in years between phases, included as a continuous variable,
divided by 10 to yield estimates of change over 10 years), age
at phase 5 (included as a categorical variable), and interaction
between time and age (thereby enabling the rate of change to
vary by age at baseline). Previous studies have suggested sex
differences in autonomic nervous system functioning. Inter-
action terms suggested sex difference in the association
between age and HR trajectories (P=0.074), leading us to
stratify all analyses by sex. In the second set of models, 5 key
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covariates (cardiometabolic problems, medication use [other
than beta blockers] versus those not on medication, SES,
ethnicity, and adherence to WHO physical activity guidelines)
were included to explore their temporal association with HR
and HRV. The following 3 age-adjusted coefﬁcients were of
interest, using cardiometabolic condition incidence as an
example: (1) The coefﬁcient for time represented the 10-year
change in HR or HRV for participants in the reference
category (ie, no cardio-metabolic condition), (2) the coefﬁcient
for cardiometabolic condition represented the difference in
HR or HRV between the no cardiometabolic condition and
cardiometabolic condition groups at baseline (phase 5), and
(3) the coefﬁcient for the interaction between time and
cardiometabolic condition represented the difference in the
10-year rate of change between participants with and without
cardiometabolic condition. As we focused on medications
associated with potential decreases in HRV, we excluded
participants using beta blockers in primary analyses. In
secondary analyses, we focused speciﬁcally on the rates of
change in HR and HRV for the participants who reported use
of beta blockers at any phase over the 10-year period.
Sensitivity analyses were also run focusing speciﬁcally on a
subset of “healthy” participants, namely, those who were free
of a cardiometabolic condition and had no reported medica-
tion use over the 10-year period.
Results
Of the 10 308 participants at phase 1 (1985–1988), 306 died
and 752 dropped out of the study before the start of HR and
HRV data collection at phase 5 (1997–1999). Of the 9250
remaining participants, HR and HRV measures were obtained
from 3365, 4095, and 5624 participants at phases 5, 7, and
9, respectively. A total of 6410 participated in ≥1 of the 3 HR
and HRV assessments over 10 years; 4414 had ≥2 assess-
ments of HR and HRV over the 10-year follow-up. Two-thirds
(2756) of the 4414 participants in the analytical sample
contributed 2 waves of HR and HRV data, and 1658 (37.6%)
contributed all 3 waves. The analytical sample was composed
of more men than women (70.8% versus 59.9%; P<0.001) and
persons from the high employment grade (43.2% versus
35.1%; P<0.001). In participants with only 1 measure, the
mean estimates of HR and LF-HRV were slightly higher and
lower, respectively, for both sexes at phase 5 compared with
the main analysis. Table S1A compares the characteristics at
phase 5 for participants with 1 HR and HRV assessment
versus ≥2 assessments. Compared with participants with 1
assessment, the analytical sample was composed of more
men than women (72.0% versus 68.4%; P=0.004), more
persons in the youngest age category (22.9% versus 20.3%
aged 44–49 years at phase 5; P<0.001), and persons from the
high employment grade (45.1% versus 38.6%; P<0.001). The
difference in the prevalence of cardiometabolic conditions
was not statistically signiﬁcant.
Table 1 presents the descriptive characteristics of the
analytical sample at phases 5, 7, and 9 by age, civil service
grade, ethnicity, presence of cardiometabolic problems,
medication use, and adherence to WHO physical activity
guidelines. The majority of participants were of white
European origin. Table S1B presents the Spearman rank
correlation coefﬁcients between HR and HRV at phase 5.
Strong positive correlations were found between all HRV
measures except for LFnu, ranging from 0.74 (LF-HRV and HF-
HRV) to 0.90 (LF-HRV and SDNN). Correlations between HRV
and HR were negative and lower in magnitude: r=0.47 for
SDNN, r=0.37 for LF-HRV, and r=0.42 for HF-HRV.
Table 2 presents the age-adjusted means at phases 5, 7,
and 9 for the subset of 1658 participants with HR and HRV
measurements at all 3 phases. Average levels of HR, SDNN,
and LF- and HF-HRV decreased consistently for men but
increased for women from phase 5 to 7. These HRV
measures, however, declined signiﬁcantly for both sexes over
the 10-year follow-up. HF-HRV, for example, decreased by
30.6% for men and 32.8% for women over the 10-year period.
LFnu did not change signiﬁcantly over the 10-year period.
Table 3 presents the results from the mixed models that
estimated associations between age at baseline and HR and
HRV trajectories. Age-speciﬁc rates of change over the 10-
year follow-up estimated from each model are presented in
Table 4. Results indicated signiﬁcant decreases in SDNN, LF-
HRV, HF-HRV, and HR; however, the interaction terms
between age at baseline and time showed signiﬁcant
differences in the rate of decline in LF-HRV for women, in
HF-HRV for men and for women, and in LFnu for men. Younger
participants at baseline experienced faster decline in HF-HRV
than their older counterparts (P=0.001 and P=0.020 for the
time9age interaction term for men and for women, respec-
tively). Change in HF-HRV for men aged ≥60 years at baseline,
for example, was 13% over 10 years compared with 52%
for men aged 44 to 49 years (see Table 4). In the case of
LFnu, older men at baseline (aged 54–59 and ≥60 years)
experienced decreases in LFnu compared with no change in
the youngest men (aged 44–49 years). Declines in HR and
SDNN for women showed marginally signiﬁcant differences in
the rate of change across age groups (P=0.063 and P=0.060)
(Table 3).
Table 5 presents results from the mixed-models analysis
undertaken to assess associations among cardiometabolic
condition, medication use (other than beta blockers), and HR
and HRV trajectories. At baseline, cardiometabolic condition
was signiﬁcantly associated with lower values of SDNN, LF-
HRV, and HF-HRV for both sexes and lower values of LFnu for
men. For men, cardiometabolic condition had no signiﬁcant
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effect on the rate of decline in HRV measures. For women,
cardiometabolic condition was associated with faster rates of
decline in SDNN, LF-HRV, and LFnu. At baseline, reported use
of prescribed medication (other than beta blockers) was
associated with signiﬁcantly lower values of SDNN, LF-HRV,
and HF-HRV for men and for women and with higher values of
HR for men. Differences in the rate of change in HR and HRV
by medication group were not signiﬁcant for either sex. The
dynamics of HR and HRV change over time by cardiometabolic
condition and reported medication use (other than beta
blockers) are presented in Figures 1 and 2, respectively.
In secondary analyses, reported use of beta blockers at
baseline was associated with signiﬁcantly lower values of HR,
LF-HRV, and LFnu for men and for women and signiﬁcantly
higher values of HF-HRV for women. Reported use of beta
blockers over 10 years was signiﬁcantly associated with
faster declines in SDNN and LF-HRV for women (P=0.029 and
P=0.032) but not for men (data not shown).
HR and HRV Trajectories by SES, Ethnicity, and
Habitual Physical Activity
At each phase, average levels of SDNN for men in the high
employment grade were highest and average levels of HR
were lower than for men in the middle and low grades.
Average levels of HR were lower for women in the high
Table 1. Descriptive Characteristics of Analytical Sample by Data Collection Phase and Sex
Phase 5 (1997–1999) Phase 7 (2002–2004) Phase 9 (2007–2009)
Men Women Men Women Men Women
n 1962 756 2648 1066 2940 1114
Age, y
44–49, n (%) 457 (23.3) 166 (22.0) 608 (23.0) 224 (21.0) 692 (23.5) 257 (23.1)
50–54, n (%) 600 (30.6) 196 (25.9) 803 (30.3) 303 (28.4) 917 (31.2) 330 (29.6)
55–59, n (%) 395 (20.1) 160 (21.2) 566 (21.4) 248 (23.3) 615 (20.9) 257 (23.1)
60–69, n (%) 510 (26.0) 234 (31.0) 671 (25.3) 291 (27.3) 716 (24.4) 270 (24.2)
Civil service grade
High, n (%) 1080 (55.5) 134 (18.0) 1360 (52.9) 243 (23.4) 1547 (54.1) 254 (23.4)
Medium, n (%) 776 (39.9) 360 (48.3) 1094 (42.6) 484 (46.7) 1201 (42.0) 517 (47.7)
Low, n (%) 89 (4.6) 252 (33.8) 115 (4.5) 310 (29.9) 114 (4.0) 313 (28.9)
Ethnicity
White, n (%) 1850 (94.3) 643 (85.1) 2476 (93.5) 911 (85.6) 2760 (93.9) 953 (85.6)
South Asian, n (%) 80 (4.1) 55 (7.3) 118 (4.5) 80 (7.5) 120 (4.1) 78 (7.0)
African Caribbean, n (%) 22 (1.1) 48 (6.4) 38 (1.5) 60 (5.6) 40 (1.4) 66 (5.9)
Other, n (%) 9 (0.5) 9 (1.2) 12 (0.5) 4 (1.3) 16 (0.6) 16 (1.5)
Cardiometabolic c., n (%)* 852 (43.4) 348 (46.0) 1326 (50.1) 591 (55.4) 1666 (56.7) 672 (60.3)
CHD, n (%) 239 (12.2) 130 (17.2) 401 (15.1) 202 (19.0) 536 (18.2) 229 (20.6)
Medication use, n (%) 685 (35.2) 414 (55.1) 1340 (50.9) 677 (63.7) 2311 (78.7) 934 (83.9)
CVD medication, n (%) 267 (13.7) 109 (14.5) 710 (27.0) 297 (27.9) 1525 (51.9) 543 (48.8)
Beta blockers, n (%) 76 (3.9) 41 (5.5) 226 (8.6) 90 (8.5) 278 (9.5) 86 (7.7)
CNS medication, n (%) 51 (2.6) 37 (4.9) 102 (3.9) 62 (5.8) 142 (4.8) 95 (8.5)
Antidepressants, n (%) 35 (1.8) 30 (4.0) 69 (2.6) 45 (4.2) 102 (3.5) 71 (6.4)
Adherence to WHO physical activity recommendations
Hardly ever, n (%) 1302 (74.3) 539 (83.2) 1766 (74.9) 776 (83.5) 2002 (74.7) 841 (83.5)
Sometimes, n (%) 270 (15.4) 66 (10.2) 353 (15.0) 92 (9.9) 412 (15.4) 99 (9.8)
Always, n (%) 180 (10.3) 43 (6.6) 239 (10.1) 61 (6.6) 266 (9.9) 67 (6.7)
Whitehall II study participants with ≥2 assessments of heart rate and heart rate variability over 10-year follow-up. CHD indicates coronary heart disease; CNS, central nervous system; CVD,
cardiovascular disease; WHO, World Health Organization.
*Presence of any of the following cardiometabolic conditions: diagnosed CHD, stroke, heart failure, diabetes, obesity, and hypertension. Habitual physical activity over the 10-year period
was categorized as hardly ever (once or less through follow-up), sometimes (in 2 phases), or always (in all 3 follow-up phases) meeting the WHO guidelines.
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employment grade. Differences in the rate of change in HR
and HRV across SES were not statistically signiﬁcant
(Table S2A and S2B). For both sexes, average values of LFnu
were signiﬁcantly higher, and for men, values of HF-HRV were
signiﬁcantly lower for participants of white ethnic origin.
Differences in the rate of change across the white and
nonwhite ethnic minority groups were not statistically signif-
icant (Table S3A and S3B). For men who consistently adhered
to the WHO physical activity guidelines (at least 1 hour of
vigorous activity 3 times or 2.5 hours of moderate activity 5
times per week) over the 10-year period, average levels of
SDNN, LF-HRV, and HF-HRV were higher and average levels of
HR were lower than for men who met the guidelines on ≤1
occasion. Differences in the rate of change across the
physical activity groups were not signiﬁcant for HRV in either
sex and were not signiﬁcant for HR for men. For women,
levels of adherence to WHO guidelines were associated with
differences in the rate of change in HR. Compared with
women who met the guidelines on ≤1 occasion throughout
10-year follow-up, women who met the guidelines on each
occasion showed a faster pace of decline in HR (Table S4A
and S4B).
Discussion
The main ﬁnding in this large longitudinal UK population-
based study is that HRV decreased with aging independent of
pathological conditions or medication use, potentially sug-
gesting that cardiac autonomic modulation diminishes due to
normative aging. Men and women showed similar rates of
HRV decline, with faster decline in younger age groups.
Cross-sectionally, average levels of HRV were lower for men
than for women, for participants with cardiometabolic con-
dition, and for participants reporting the use of prescribed
medications other than beta blockers. We further observed
that women with a cardiometabolic condition experienced
faster decline in SDNN, LF-HRV, and LFnu compared with
women without a cardiometabolic condition. SES, ethnicity,
and habitual physical activity did not show statistically
signiﬁcant associations with longitudinal HRV trajectories.
Finally, women who met the WHO physical activity guidelines
on each occasion over 10-year follow-up showed a faster
pace of decline in HR than women who met the guidelines on
≤1 occasion.
Average levels of SDNN, LF-HRV, and HF-HRV in this large
UK middle-aged cohort were similar to levels seen in
population-based studies in the United States19 and Ger-
many38 based on short-term HRV recordings measured using
similar procedures. Given the dearth of longitudinal studies of
patterns of HRV changes with aging, it is important that our
current study replicated most of the cross-sectional evidence
of HRV declines with aging.10,12–14 Our study is unique in
demonstrating age-related HRV changes based on short-term
recordings. Most of the cross-sectional10,11,14,15 and longitu-
dinal17,22 evidence on age-related changes in HRV has been
Table 2. Age-Adjusted Heart Rate and Heart Rate Variability
Means (95% CI) at Baseline and 5- and 10-Year Follow-Up by
Sex
Men Women
n 1198 460
HR, bpm
Phase 5 68.3 (67.7–68.9) 70.4 (69.4–71.4)
Phase 7 66.6 (65.9–67.2) 67.3 (66.3–68.3)
Phase 9 66.7 (66.1–67.3) 68.9 (67.9–69.8)
Mean change
per 10 years
1.6 (2.1 to 1.1) 1.5 (2.3 to 0.7)
SDNN, ms*
Phase 5 34.8 (34.0–35.7) 33.1 (31.9–34.4)
Phase 7 33.6 (32.8–34.5) 34.7 (33.3–36.2)
Phase 9 30.2 (29.4–31.1) 29.3 (28.1–30.7)
Percentage
change per
10 years
13.6 (16.4 to 10.8) 11.7 (16.2 to 7.2)
LF-HRV, ms2*
Phase 5 337.7 (320.8–355.4) 259.1 (238.5–281.4)
Phase 7 294.9 (278.7–311.9) 273.1 (249.4–299.1)
Phase 9 235.8 (221.6–250.9) 196.5 (177.7–217.2)
Percentage
change per
10 years
34.2 (40.2 to 28.2) 26.7 (36.4 to 17.7)
HF-HRV, ms2*
Phase 5 121.4 (114.2–128.9) 145.3 (131.8–160.2)
Phase 7 112.5 (105.3–120.2) 150.3 (135.1–167.2)
Phase 9 87.9 (82.1–94.2) 103.7 (92.8–115.9)
Percentage
change per
10 years
30.6 (37.4 to 23.7) 32.8 (43.8 to 21.8)
LFnu (%)
Phase 5 71.9 (71.1–72.7) 62.7 (61.4–64.0)
Phase 7 70.7 (69.9–71.5) 63.3 (62.0–64.6)
Phase 9 71.1 (70.3–72.0) 63.9 (62.5–65.2)
Mean change
per 10 years
0.8 (1.7 to 0.1) 1.2 (0.3 to 2.6)
Whitehall II study participants with assessment of HR and HRV at each phase over the
10-year follow-up. bpm indicates beats per minute; HF-HRV, high-frequency heart rate
variability; HR, heart rate; LF-HRV, low-frequency heart rate variability; LFnu, low-
frequency heart rate variability in normalized units; SDNN, standard deviation of all
intervals between R waves with normal-to-normal conduction.
*Geometric means calculated due to skewed distributions.
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Table 3. Associations (Mixed-Models Analyses) Between Age at Baseline and Heart Rate and Heart Rate Variability Trajectories by
Sex
Men (n=3176) Women (n=1238)
b SE P Value b SE P Value
HR, beats/min
Intercept 68.053 0.405 <0.001 69.175 0.594 <0.001
Time, per 10 years 2.300 0.492 <0.001 1.848 0.842 0.028
Age, y
44–49* 0 0
50–54 0.054 0.537 0.920 0.721 0.790 0.362
55–59 0.737 0.589 0.211 1.201 0.834 0.150
60–69 0.229 0.564 0.685 1.547 0.800 0.053
Time9age, y
44–49* 0 0
50–54 0.592 0.651 0.363 0.346 1.139 0.761
55–59 0.343 0.726 0.637 1.730 1.217 0.155
60–69 0.787 0.691 0.255 1.412 1.150 0.220
P value† 0.689 0.063
ln SDNN, ms
Intercept 3.649 0.017 <0.001 3.673 0.026 <0.001
Time, per 10 years 0.185 0.027 <0.001 0.236 0.045 <0.001
Age, y
44–49* 0 0
50–54 0.095 0.022 <0.001 0.135 0.035 <0.001
55–59 0.159 0.024 <0.001 0.160 0.037 <0.001
60–69 0.243 0.023 <0.001 0.310 0.035 <0.001
Time9age, y
44–49* 0 0
50–54 0.045 0.036 0.210 0.068 0.060 0.261
55–59 0.016 0.040 0.693 0.072 0.064 0.263
60–69 0.077 0.038 0.042 0.163 0.061 0.007
P value† 0.187 0.060
ln LF-HRV, ms2
Intercept 6.071 0.037 <0.001 5.922 0.059 <0.001
Time, per 10 years 0.469 0.059 <0.001 0.479 0.098 <0.001
Age, y
44–49* 0 0
50–54 0.229 0.049 <0.001 0.264 0.079 0.001
55–59 0.464 0.054 <0.001 0.415 0.083 <0.001
60–69 0.664 0.052 <0.001 0.709 0.080 <0.001
Time9age, y
44–49* 0 0
50–54 0.072 0.077 0.353 0.014 0.132 0.916
Continued
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based on 24-hour HRV recordings that provide different
physiological information than short-term recordings during
which conditions are controlled and stable.5 Consequently, we
can compare our ﬁndings with only 1 other longitudinal
population-based study. In the Atherosclerosis Risk in Com-
munities (ARIC) study, the mean annual decrease in SDNN for
>6000 middle-aged men and women (aged 45–64 years) was
similar to our results.8,18,19 No studies of ARIC data have
reported on longitudinal changes of frequency-domain HRV or
on differences in HRV trajectories according to sex and/or
across age groups. An earlier study using Whitehall II data
based on 2 short-term HRV recordings20 showed that HRV
declined for men but increased for women over the 5-year
follow-up period. Using additional follow-up of HRV measure-
Table 3. Continued
Men (n=3176) Women (n=1238)
b SE P Value b SE P Value
55–59 0.063 0.086 0.469 0.166 0.141 0.239
60–69 0.189 0.082 0.022 0.317 0.133 0.017
P value† 0.139 0.049
ln HF-HRV, ms2
Intercept 5.065 0.043 <0.001 5.364 0.067 <0.001
Time, per 10 years 0.523 0.068 <0.001 0.605 0.110 <0.001
Age, y
44–49* 0 0
50–54 0.289 0.057 <0.001 0.308 0.089 0.001
55–59 0.466 0.062 <0.001 0.355 0.094 <0.001
60–69 0.634 0.059 <0.001 0.761 0.090 <0.001
Time9age, y
44–49* 0 0
50–54 0.163 0.090 0.069 0.100 0.148 0.499
55–59 0.234 0.100 0.019 0.198 0.158 0.212
60–69 0.389 0.095 0.000 0.439 0.150 0.003
P value† 0.001 0.020
LFnu (%)
Intercept 71.564 0.421 <0.001 62.599 0.781 <0.001
Time, per 10 years 1.152 0.795 0.381 2.372 1.415 0.128
Age, y
44–49* 0 0
50–54 1.272 0.558 0.508 0.536 1.225 0.662
55–59 0.025 0.613 0.446 1.577 1.293 0.223
60–69 0.803 0.577 0.023 0.815 1.240 0.511
Time9age, y
44–49* 0 0
50–54 2.056 1.103 0.062 1.231 1.996 0.537
55–59 3.800 1.231 0.002 0.278 2.132 0.896
60–69 4.278 1.172 <0.001 2.208 2.016 0.273
P value† 0.001 0.686
Whitehall II study participants with ≥2 assessments of HR and HRV over the 10-year follow-up. The 10-year rate of change is presented in Table 4. HF-HRV indicates high-frequency heart
rate variability; HR, heart rate; LF-HRV, low-frequency heart rate variability; LFnu, low-frequency heart rate variability in normalized units; SDNN, standard deviation of all intervals between
R waves with normal-to-normal conduction.
*Reference category.
†P value from adjusted Wald test.
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ments for the same cohort, we no longer observed increases
in mean HRV for women over the 10-year period. Moreover,
our analyses revealed similarities in the temporal course and
rate of decline in HRV measures for both sexes. We examined
the inﬂuence of a number of factors that could have
accounted for the unexpected increase in HRV levels for
women from phase 5 to 7, including use of hormone
replacement therapy and oral contraceptives or menopausal
status. These factors did not explain the 5-year increase in
HRV or the longer term decline in HRV over the 10-year period
(data not shown).
The cross-sectional associations found in our study
between cardiometabolic conditions (history of coronary
heart disease, heart failure, stroke, diabetes, hypertension,
and obesity) and/or cardiovascular-related medications (other
than beta blockers) and HRV levels were also in line with
previous studies.9,18–21,34,35 Participants reporting use of beta
blockers had similar or slightly more favorable HR and HRV
levels compared with untreated participants. HR and HRV
levels were much more favorable for participants using beta
blockers compared with those on other medications; however,
the beneﬁcial effects of beta blockers on sympathetic nervous
system activity36 declined for women over the 10-year follow-
up, as reﬂected by their faster rate of decline in SDNN
compared with those not taking medication. This ﬁnding
should be treated with caution because small sample sizes
meant that our study lacked sufﬁcient power to detect small
differences in the rate of change in HR and HRV according to
beta blocker use.
Although HRV decreases were inﬂuenced by car-
diometabolic condition for women, none of the 5 key
covariates fully explained the declining trend in HRV as both
Table 4. Estimated Age-Speciﬁc 10-Year Rates of Change (95% CIs) in Heart Rate and Heart Rate Variability Trajectories by Sex
HR and HRV, by
Age at Baseline Men Women
HR, bpm
44–49 y 2.3 (3.3 to 1.3) 1.8 (3.5 to 0.2)
50–54 y 1.7 (2.5 to 0.9) 1.5 (3.0 to 0.0)
55–59 y 2.0 (3.0 to 0.9) 0.1 (1.8 to 1.6)
≥60 y 1.5 (2.5 to 0.6) 3.3 (4.8 to 1.7)
SDNN, ms
44–49 y 18.5% (23.8 to 13.2) 23.6% (32.3 to 14.9)
50–54 y 14.0% (18.6 to 9.4) 16.8% (24.8 to 8.9)
55–59 y 16.9% (22.7 to 11.2) 16.4% (25.5 to 7.3)
≥60 y 10.7% (16.0 to 5.5) 7.3% (15.4 to 0.8)
LF-HRV, ms2
44–49 y 46.9% (58.3 to 35.4) 47.9% (67.0 to 28.7)
50–54 y 39.7% (49.6 to 29.7) 46.5% (63.9 to 29.1)
55–59 y 40.6% (53.1 to 28.1) 31.3% (51.2 to 11.3)
≥60 y 28.0% (39.3 to 16.6) 16.2% (34.0 to 1.6)
HF-HRV, ms2
44–49 y 52.3% (65.5 to 39.0) 60.5% (82.0 to 39.0)
50–54 y 36.0% (47.4 to 24.5) 50.5% (70.0 to 31.0)
55–59 y 28.9% (43.3 to 14.5) 40.7% (63.1 to 18.4)
≥60 y 13.3% (26.4 to 0.2) 16.6% (36.6 to 3.4)
LFnu (%)
44–49 y 1.2% (0.5 to 2.8) 2.4% (0.5 to 5.3)
50–54 y 0.9% (2.3 to 0.5) 1.1% (1.5 to 3.8)
55–59 y 2.6% (4.4 to 0.9) 2.1% (0.9 to 5.1)
≥60 y 3.1% (4.7 to 1.5) 0.2% (2.5 to 2.9)
HF-HRV indicates high-frequency heart rate variability; HR, heart rate; LF-HRV, low-frequency heart rate variability; LFnu, low-frequency heart rate variability in normalized units; SDNN,
standard deviation of all intervals between R waves with normal-to-normal conduction.
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men and women aged over the 10-year period. Our sensitivity
analysis focusing speciﬁcally on a subset of healthy partic-
ipants—those without cardiometabolic condition and with no
reported medication use at any of the 3 data collection
phases—produced largely similar results of declining HRV tra-
jectories. Although the biological interpretation of HRV indices
is complex, the decreasing SDNN and HF-HRV trajectories
may suggest that both normative and potentially pathological
aging is accompanied by gradual reduction of overall ﬂuctu-
ation in cardiac autonomic input and by gradual reduction in
parasympathetic modulation. Mechanisms underlying
changes in parasympathetic modulation with aging may be
related to changes in cholinergic and muscarinic pathways
through which vagal signal is carried. This may include
disturbed cardiac acetylcholine release response to
stimulation,39 decreases in muscarinic receptor activity,40
and reductions in M2 muscarinic receptor density with
aging,41 all of which have been shown to decrease with aging
in clinical trials. Loss of protective vagal reﬂexes seems to
hinder physical and psychological functioning and capacity to
respond ﬂexibly to efferent stimuli, resulting in increased
vulnerability to the diseases2,42 that are often prevalent at
older ages.43
Table 5. Associations (Mixed-Models Analyses) Between
Cardiometabolic Condition and Medication Use and Heart
Rate and Heart Rate Variability Trajectories by Sex
Cardiometabolic Condition
Prescribed Medication (Other
Than Beta Blockers)
b SE P Value b SE P Value
Men (n=3176) Men (n=2735)
HR,
beats/min
0.177 0.504 0.726 0.905 0.564 0.108
SDNN,
ms
0.026 0.027 0.343 0.005 0.032 0.884
LF-HRV,
ms2
0.086 0.059 0.147 0.012 0.070 0.863
HF-HRV,
ms2
0.116 0.069 0.092 0.037 0.080 0.649
LFnu (%) 0.004 0.008 0.602 0.003 0.010 0.770
Women (n=1238) Women (n=1072)
HR,
beats/min
1.099 0.848 0.195 1.281 0.980 0.191
SDNN,
ms
0.096 0.044 0.031 0.096 0.055 0.082
LF-HRV,
ms2
0.227 0.098 0.020 0.208 0.121 0.086
HF-HRV,
ms2
0.066 0.110 0.548 0.187 0.137 0.174
LFnu (%) 0.036 0.015 0.015 0.011 0.018 0.566
Estimates were obtained from mixed models including time, age at baseline, time9age,
cardiometabolic condition or medication use, and time9cardiometabolic condition or
medication use. The table shows the coefﬁcients for the time9cardiometabolic condition
or medication use interaction term. The interaction term for models including
cardiometabolic condition shows the estimated difference in the 10-year rate of change
between the no cardiometabolic condition and cardiometabolic condition groups.
Likewise, the interaction term for models including medication use shows the estimated
difference in the 10-year rate of change between participants reporting and not reporting
use of prescribed medication. HF-HRV indicates high-frequency heart rate variability; HR,
heart rate; LF-HRV, low-frequency heart rate variability; LFnu, low-frequency heart rate
variability in normalized units; SDNN, standard deviation of all intervals between R waves
with normal-to-normal conduction.
Figure 1. Model-predicted trajectories of age-related change in
HR and HRV measures in men (A) and women (B) aged 44 to
69 years (1997–1999) with and without reported cardiometabolic
condition over a 10-year follow-up period. The trajectories for
each age group at phases 5, 7, and 9 were predictions from a
linear mixed model including time, age at baseline, time9age,
cardiometabolic condition, and time9cardiometabolic condition.
Predicted values for HRV measures were based on geometric
means. HR indicates heart rate; HRV, heart rate variability; HF,
high-frequency heart rate variability; LF, low-frequency heart rate
variability; LFnu, low-frequency heart rate variability in normalized
units; SDNN, standard deviation of all intervals between R waves
with normal-to-normal conduction.
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Trajectories in LF-HRV, measured in the supine position in
our study, changed in the same direction and in a similar
pattern to HF-HRV, suggesting that LF-HRV not only is a
measure of sympathetic activity, as reported in some studies,
but also represents the variation in RR interval caused by
more graduated interplay between sympathetic and parasym-
pathetic activities.5
Our results may also provide possible insight into plausible
biological pathways of sex differences in cardiac autonomic
functioning. Cardiometabolic conditions affected HRV trajec-
tories for women but not for men. In addition, we observed
differences in LFnu trajectories by sex that may reﬂect sex-
speciﬁc differences in balance between the 2 branches of
autonomic nervous system with aging. A number of author-
ities22,44 have suggested that the parasympathetic and
sympathetic branches of the autonomic nervous system
operate differently for men and for women to achieve
homeostasis. The observed sex differences in our study may
thus be related to different biological ways of responding to
stress44 and/or health conditions.45 The exact mechanisms
underlying sex differences in cardiac autonomic functioning,
however, are poorly understood.22
Strengths and Limitations
A key strength of our investigation is the use of participant-
level longitudinal data with 3 repeated measures of HRV over
a decade in a nonclinical setting. Multiple measures of short-
term HRV in both the time and frequency domains allowed us
to attribute HRV changes to parasympathetic or/and sympa-
thetic modulation changes and generally to changes in
cardiac autonomic function. We used repeated measures of
covariates, not just baseline measures, allowing the presence
of cardiometabolic condition and reported medication use to
vary over the 10-year period. The analytical sample for our
study was reduced in size due to death and nonresponse or
withdrawal from the study prior to the start of HR and HRV
data collection in phase 5 and through staff not being
available for 2 months at phase 5. In addition, we restricted
the analytical sample to the subset of participants with at
least 2 HRV measurements to estimate within-person change
in HR and HRV levels. Although the sizeable amount of
missing data at phase 5 has been shown to be random,24 the
observed declines in HRV are most likely underestimated to
some extent in our study because of a healthy survival bias
(selective attrition in the cohort); those with the presence of
risk factors or low HRV levels may be more likely to drop
out.46
Sample sizes were too small to examine the age- and sex-
speciﬁc trajectories for nonwhite minority ethnic groups such
as people of South Asian and African Caribbean origin. We
cannot rule out the contribution of device effects because
different recording equipment was used in each phase;
however, the HRV protocols were consistent across all data
collection phases. Although 5-minute HRV recordings are
highly repeatable47 and considered representative of 24-hour
ambulatory HRV recordings,48 long-term recordings may offer
more comprehensive and accurate evaluation of HRV changes
over time.
Finally, the Whitehall II study is an occupation-based cohort
and thus is healthier on average than the general population.
Figure 2. Model-predicted trajectories of age-related change in
HR and HRV measures in men (A) and women (B) aged 44 to
69 years (1997–1999) with and without reported medication use
(other than beta blockers) over a 10-year follow-up period. The
trajectories for each age group at phases 5, 7, and 9 were
predictions from a linear mixed model including time, age at
baseline, time9age, use of prescribed medication, and
time9medication use. Predicted values for HRV measures were
based on geometric means. HR indicates heart rate; HRV, heart
rate variability; HF, high-frequency heart rate variability; LF, low-
frequency heart rate variability; LFnu, low-frequency heart rate
variability in normalized units; SDNN, standard deviation of all
intervals between R waves with normal-to-normal conduction.
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Nevertheless, etiological ﬁndings from the Whitehall II cohort
have been shown to be comparable to other population-based
studies.49
Conclusion
Our study shows that normative HRV-declining trajectories
exist largely independently of cardiometabolic conditions or
reported use of medication. We have further described the
age-related progression of HRV according to sex, ethnicity,
SES, and habitual physical activity, and that information could
help improve understanding of cardiac autonomic functioning
in aging populations.
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